# DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer

Source: https://onco.cc/trials/nct06178159/  
OnCo record `nct06178159` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Disitamab vedotin, Pertuzumab and Toripalimab in HER2-positive breast cancer, run by RemeGen Co., Ltd., now recruiting.

## Summary

DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer is a phase 2 interventional study registered as NCT06178159 by RemeGen Co., Ltd., with 40 participants planned, started 2023-11-28 and due to reach its primary completion in 2026-06. Interventions recorded: Disitamab Vedotin Injection, Pertuzumab Injection and Toripalimab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06178159
- Phase: 2
- Setting: A Phase II, Multicenter, Open-Label Neoadjuvant Study to Evaluate the Safety and Efficacy of Disitamab Vedotin in Combination With Pertuzumab With or Without Toripalimab for HER2 Positive Breast Cancer
- Sponsor: RemeGen Co., Ltd.
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT06178159: https://clinicaltrials.gov/study/NCT06178159

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- drugs: [Disitamab vedotin](https://onco.cc/drugs/disitamab-vedotin/), [Pertuzumab](https://onco.cc/drugs/pertuzumab/), [Toripalimab](https://onco.cc/drugs/toripalimab/)
- companies: [RemeGen](https://onco.cc/companies/remegen/)

---
JSON: https://onco.cc/api/v1/entities/nct06178159.json